EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study

Yang Li, Zhenzhen Wang, Tongsheng Chu, Hong Wang, Lijiao Yin, Shujuan Yuan, Yonghong Wang, Gang Li, Hong Liu, Furen Zhang

PLOS Neglected Tropical Diseases · 17.03.2026 · 20 (3) · e0014114

DOI: 10.1371/journal.pntd.0014114 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 17.03.2026. Verfasst von Yang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Dapsone, Leprostatic Agents, HLA-B13 Antigen, Leprosy, Multibacillary. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Laboratory of Sedimentary Mineralization and Sedimentary Minerals in Shandong Province, Joint Innovation Team for Clinical & Basic Research, Taishan Scholar Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In HLA-B*13:01 -positive multibacillary (MB) leprosy patients, dapsone-containing multidrug therapy (MDT) carries a high risk of dapsone hypersensitivity syndrome (DHS). Alternative regimens (dapsone-free) are adopted, but their long-term efficacy compared with standard MDT in HLA-B*13:01 -negative patients remains inadequately characterized. Methodology This retrospective cohort study analyzed MB patients (2015–2023) from the National Leprosy Prevention and Control Management Information System (LEPMIS) with ≥1-year follow-up. Primary outcomes (cure/relapse rates, bacterial index (BI), leprosy reactions, and disability progression) and secondary outcomes (adverse events and treatment duration) were compared between HLA-B*13:01 -positive patients receiving alternative therapy (rifampicin + clofazimine ± clarithromycin/ofloxacin/minocycline) and negative patients receiving standard MDT (rifampicin + clofazimine + dapsone).

Findings

Among the 271 enrolled MB patients (120 HLA-B*13:01 -positive, 151 negative), alternative therapy showed comparable efficacy to standard MDT in cure rates (67.6% vs. 65.8% at Year 5), the rate of BI decline (89.92% vs. 95.11% at Year 5), smear negativity rates (71.43% vs. 75.00% at Year 5) and relapse rates (0.46 vs. 0.20 per 100 person-years). Kaplan-Meier survival functions revealed no significant differences in leprosy reactions or disability progression. Additionally, alternative therapy demonstrated comparable safety to MDT (1.67% vs. 2.65%, P = 0.70).

Conclusions

In our study, dapsone-free alternative regimens demonstrated comparable clinical efficacy and safety to standard MDT in MB patients, providing a viable option for HLA-B*13:01 carriers. These findings, limited by the observational design and regimen heterogeneity, warrant further investigation in prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DapsoneLeprostatic AgentsHLA-B13 AntigenLeprosy, MultibacillaryLeprosyHumansMaleFemaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeDrug Therapy, CombinationClofazimineRifampinAgedYoung AdultAdolescent

Substanzen

DapsoneLeprostatic AgentsClofazimineHLA-B13 AntigenRifampin

Autor:innen und Institutionen

  • School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Dermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
  • Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Guangxi Provincial Institute of Dermatology, Nanning, Guangxi, China.
  • Wenshan Prefecture Dermatology Prevention and Treatment Institute (Wenshan Prefecture Dermatology Specialist Hospital), Wenshan, Yunnan, China.
  • Hunan Provincial Center for Disease Control and Prevention (Hunan Academy of Preventive Medicine), Changsha, Hunan, China.

Förderung

  • Key Laboratory of Sedimentary Mineralization and Sedimentary Minerals in Shandong Province
  • Joint Innovation Team for Clinical & Basic Research
  • Taishan Scholar Foundation of Shandong Province

Zitieren

APA

Li, Y., Wang, Z., Chu, T., Wang, H., Yin, L., Yuan, S., Wang, Y., Li, G., Liu, H., & Zhang, F. (2026). Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study. PLOS Neglected Tropical Diseases, 20(3), e0014114. https://doi.org/10.1371/journal.pntd.0014114

Vancouver

Li Y, Wang Z, Chu T, Wang H, Yin L, Yuan S, et al. Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study. PLOS Neglected Tropical Diseases. 2026;20(3):e0014114. doi:10.1371/journal.pntd.0014114

BibTeX
@article{Li2026,
  author = {Li, Yang and Wang, Zhenzhen and Chu, Tongsheng and Wang, Hong and Yin, Lijiao and Yuan, Shujuan and Wang, Yonghong and Li, Gang and Liu, Hong and Zhang, Furen},
  title = {Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  volume = {20},
  number = {3},
  pages = {e0014114},
  doi = {10.1371/journal.pntd.0014114}
}
Kostenlos starten →